Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filtering shows promise for high lipoprotein(a) in dialysis patients

NCT ID NCT07390604

Completed Disease control Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small completed study looked at a blood filtering procedure called double-filtration plasmapheresis (DFPP) in 5 kidney dialysis patients with very high levels of lipoprotein(a), a fatty substance linked to heart disease and blood clots. The goal was to see if DFPP could lower those levels and possibly reduce cardiovascular risk. The study measured Lp(a) before and after each session, but because it was a tiny case series without a comparison group, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Double-filtration plasmapheresis (DFPP)

What this could lead to

If this works, it could point toward a way to lower heart and clot risks in kidney dialysis patients with very high lipoprotein(a).

What could go wrong

This is a tiny case series (5 people) with no control group, so results may not apply to others. The procedure is invasive and not a long-term fix.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic renal failure syndrome dialysis disequilibrium syndrome end stage renal failure venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOUBLE-FILTRATION PLASMAPHERESIS END STAGE CHRONIC RENAL FAILURE HEMODIALYSIS COMPLICATION LIPOPROTEIN(A) LIPOPROTEIN-APHERESIS

Contacts and locations

Locations

  • CHR Metz-Thionville Hopital de Mercy

    Metz, 57085, France